cilostazol has been researched along with Koch's Disease in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We analyzed the time to death in Mycobacterium tuberculosis-infected mice receiving type 4 PDE-Is (rolipram and cilomilast) and the impact on bacterial burden, time to clearance, and relapse when types 3 and 5 PDE-Is (cilostazol and sildenafil, respectively) and rolipram were added to the standard treatment." | 3.79 | Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. ( Ammerman, NC; Bishai, WR; Maiga, M; Maiga, MC; Murphy, R; Polis, M; Siddiqui, S; Tounkara, A, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maiga, M | 2 |
| Ammerman, NC | 2 |
| Maiga, MC | 2 |
| Tounkara, A | 1 |
| Siddiqui, S | 1 |
| Polis, M | 1 |
| Murphy, R | 1 |
| Bishai, WR | 2 |
| Agarwal, N | 1 |
| Gupta, R | 1 |
| Guo, H | 1 |
| Lun, S | 1 |
2 other studies available for cilostazol and Koch's Disease
| Article | Year |
|---|---|
Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment.
Topics: Animals; Antitubercular Agents; Bacterial Load; Cilostazol; Disease Models, Animal; Drug Interaction | 2013 |
Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model.
Topics: Animals; Antitubercular Agents; Cilostazol; Disease Models, Animal; Mice; Phosphodiesterase Inhibito | 2012 |